{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:53:53Z","timestamp":1762458833527,"version":"build-2065373602"},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.jaad.2010.01.061","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T06:40:55Z","timestamp":1284705655000},"page":"549-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cutaneous toxicities of antiretroviral therapy for HIV"],"prefix":"10.1016","volume":"63","author":[{"given":"Camille E.","family":"Introcaso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet M.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie L.","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.01.061_bib1","unstructured":"Joint United Nations Programme on HIV\/AIDS. 2008 report on the global AIDS epidemic. http:\/\/data.unaids.org\/pub\/GlobalReport\/2008\/jc1510_2008_global_report_pp1_10_en.pdf\u00a0ed. Geneva, Switzerland: UNAIDS and WHO; 2008."},{"key":"10.1016\/j.jaad.2010.01.061_bib2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.01.061_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.qai.0000188123.15493.43","article-title":"Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern india","volume":"41","author":"Kumarasamy","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.01.061_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/apc.2007.0093","article-title":"Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients","volume":"22","author":"Kumarasamy","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1468-1293.2007.00477.x","article-title":"Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women","volume":"8","author":"Phanuphak","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/jac\/dki143","article-title":"Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability","volume":"55","author":"Cressey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaad.2010.01.061_bib7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1086\/428833","article-title":"Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children","volume":"40","author":"Pelton","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4103\/0378-6323.41368","article-title":"Adverse effects of antiretroviral treatment","volume":"74","author":"Sharma","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2010.01.061_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/tropej\/fmi086","article-title":"Adverse effects of antiretroviral therapy in HIV-1 infected children","volume":"52","author":"Shah","year":"2006","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.jaad.2010.01.061_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/apc.2006.20.6","article-title":"Appearance-related side effects of HIV-1 treatment","volume":"20","author":"Hawkins","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1742-1241.2007.01385.x","article-title":"Long-term complications of antiretroviral therapy: lipoatrophy","volume":"61","author":"Waters","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jaad.2010.01.061_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00128071-200708040-00004","article-title":"Dermatologic adverse effects of antiretroviral therapy: recognition and management","volume":"8","author":"Luther","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1086\/338811","article-title":"Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients","volume":"34","author":"Chene","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1053\/meta.2002.34704","article-title":"Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy","volume":"51","author":"Hadigan","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.jaad.2010.01.061_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.01.061_bib17","unstructured":"Haubrich R, Riddler SA, DiRienzo AG, Komarow L, Powderly W, Garren KW, et\u00a0al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection, abstract #38. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007."},{"key":"10.1016\/j.jaad.2010.01.061_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.asj.2008.04.009","article-title":"Lipodystrophy in the patient with HIV: social, psychological, and treatment considerations","volume":"28","author":"Peterson","year":"2008","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.jaad.2010.01.061_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2004.00190.x","article-title":"A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection","volume":"5","author":"Moyle","year":"2004","journal-title":"HIV Med"},{"issue":"3 suppl","key":"10.1016\/j.jaad.2010.01.061_bib20","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1097\/01.prs.0000234847.36020.52","article-title":"Prospective, open-label, 18-month trial of calcium hydroxylapatite (radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability","volume":"118","author":"Silvers","year":"2006","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2010.01.061_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1067\/mjd.2002.119105","article-title":"Cutaneous manifestations of antiretroviral therapy","volume":"46","author":"Ward","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00002030-200001070-00005","article-title":"Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study","volume":"14","author":"Saint-Marc","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-108-5-777_2","article-title":"Nail pigmentation and azidothymidine","volume":"108","author":"Vaiopoulos","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.7326\/0003-4819-107-6-943_2","article-title":"Nail pigmentation in the acquired immunodeficiency syndrome (AIDS)","volume":"107","author":"Panwalker","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-107-2-350","article-title":"Nail pigmentation changes associated with azidothymidine (zidovudine)","volume":"107","author":"Furth","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/archderm.1988.01670100068021","article-title":"Zidovudine-induced nail pigmentation","volume":"124","author":"Azon-Masoliver","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archderm.1989.01670210123028","article-title":"Azidothymidine-induced hyperpigmentation of skin and nails","volume":"125","author":"Bendick","year":"1989","journal-title":"Arch Dermatol"},{"issue":"2 pt 2","key":"10.1016\/j.jaad.2010.01.061_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0190-9622(90)70039-K","article-title":"Nail and mucocutaneous hyperpigmentation with azidothymidine therapy","volume":"22","author":"Greenberg","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1346-8138.2004.tb00591.x","article-title":"Pigmentation: a potential cutaneous marker for AIDS?","volume":"31","author":"Grover","year":"2004","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib30","first-page":"460","article-title":"Diffuse pigmentation (nail, mouth and skin) associated with HIV infection","volume":"124","author":"Granel","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.01.061_bib31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0030-4220(93)90013-T","article-title":"White lichenoid lesions of the buccal mucosa in patients with HIV infection","volume":"76","author":"Ficarra","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.jaad.2010.01.061_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/j.1875-9114.1996.tb02919.x","article-title":"Alopecia associated with zidovudine therapy","volume":"16","author":"Geletko","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2010.01.061_bib33","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1001\/archinte.1988.00380100134031","article-title":"Heightened cutaneous reactions to mosquito bites in patients with acquired immunodeficiency syndrome receiving zidovudine","volume":"148","author":"Diven","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib34","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJM199106273242616","article-title":"Excessive growth of eyelashes in a patient with AIDS being treated with zidovudine","volume":"324","author":"Klutman","year":"1991","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/archinte.1992.00400160138027","article-title":"Zidovudine-induced leukocytoclastic vasculitis","volume":"152","author":"Torres","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1529-8019.2005.05004.x","article-title":"Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients","volume":"18","author":"Kong","year":"2005","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.01.061_bib37","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/clinids\/20.5.1387","article-title":"Hypersensitivity of zidovudine: report of a case of anaphylaxis and review of the literature","volume":"20","author":"Wassef","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/clinids\/23.3.640","article-title":"Fatal toxic epidermolysis induced by zidovudine","volume":"23","author":"Murri","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"suppl\u00a05","key":"10.1016\/j.jaad.2010.01.061_bib39","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/clinids\/12.Supplement_5.S552","article-title":"Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily","volume":"12","author":"Cooley","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib40","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJM199005103221902","article-title":"Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial","volume":"322","author":"Cooley","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/0140-6736(92)92330-I","article-title":"Xerostomia associated with didanosine","volume":"340","author":"Dodd","year":"1992","journal-title":"Lancet"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaad.2010.01.061_bib42","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/clinids\/16.Supplement_1.S46","article-title":"Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine","volume":"16","author":"Allan","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib43","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(94)92111-3","article-title":"Cutaneous vasculitis associated with didanosine","volume":"344","author":"Herranz","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.01.061_bib44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0140-6736(92)92740-7","article-title":"Didanosine as probable cause of Stevens-Johnson syndrome","volume":"340","author":"Parneix-Spake","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.01.061_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000246003","article-title":"Dideoxyinosine-associated Ofuji papuloerythroderma in an HIV-infected patient","volume":"195","author":"Just","year":"1997","journal-title":"Dermatology"},{"year":"2007","series-title":"Videx [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib46"},{"key":"10.1016\/j.jaad.2010.01.061_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/14740338.1.4.307","article-title":"Adverse effects of antiretroviral therapy: focus on orofacial effects","volume":"1","author":"Diz Dios","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2010.01.061_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/135965350701200303","article-title":"Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz","volume":"12","author":"Vigano","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jaad.2010.01.061_bib49","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/529384","article-title":"Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study","volume":"46","author":"McComsey","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib50","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/jac\/dkn097","article-title":"Changes in metabolic toxicity after switching from stavudine\/didanosine to tenofovir\/lamivudine\u2014a staccato trial substudy","volume":"61","author":"Ananworanich","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaad.2010.01.061_bib51","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/00002030-200007280-00015","article-title":"A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)","volume":"14","author":"Squires","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib52","first-page":"227","article-title":"Lamivudine (3TC)-induced contact dermatitis","volume":"65","author":"Smith","year":"2000","journal-title":"Cutis"},{"year":"2006","series-title":"Epivir [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib53"},{"issue":"suppl\u00a02","key":"10.1016\/j.jaad.2010.01.061_bib54","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1086\/313859","article-title":"Management of the adverse effects of antiretroviral therapy and medication adherence","volume":"30","author":"Max","year":"2000","journal-title":"Clin Infect Dis"},{"year":"2008","series-title":"Abacavir [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib55"},{"key":"10.1016\/j.jaad.2010.01.061_bib56","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1086\/339751","article-title":"Abacavir hypersensitivity reaction","volume":"34","author":"Hewitt","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib57","first-page":"222","article-title":"A near-fatal hypersensitivity reaction to abacavir: case report and literature review","volume":"11","author":"Shapiro","year":"2001","journal-title":"AIDS Read"},{"key":"10.1016\/j.jaad.2010.01.061_bib58","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/00002030-199905280-00022","article-title":"Anaphylaxis after rechallenge with abacavir","volume":"13","author":"Walensky","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib59","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/00002030-199907300-00026","article-title":"Abacavir rechallenge has to be avoided in case of hypersensitivity reaction","volume":"13","author":"Escaut","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00002030-200401230-00041","article-title":"Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient","volume":"18","author":"El-Sahly","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00002030-200101260-00027","article-title":"Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity","volume":"15","author":"Frissen","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib62","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.01.061_bib63","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B\u22175701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib64","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jac\/dkm243","article-title":"Incidence of abacavir hypersensitivity and its relationship with HLA-B\u22175701 in HIV-infected patients in Taiwan","volume":"60","author":"Sun","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaad.2010.01.061_bib65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","article-title":"Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western Australian HIV cohort study","volume":"43","author":"Rauch","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib66","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B\u22175701 and a haplotypic Hsp70-hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2010.01.061_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pst.286","article-title":"PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events","volume":"7","author":"Hughes","year":"2008","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jaad.2010.01.061_bib68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","article-title":"Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations","volume":"5","author":"Hughes","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2010.01.061_bib69","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-3156.2007.01973.x","article-title":"Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine\/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)","volume":"13","year":"2008","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jaad.2010.01.061_bib70","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b\u22175701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e318046ea31","article-title":"Prospective screening for human leukocyte antigen-B\u22175701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population","volume":"45","author":"Zucman","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.01.061_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/sti.2006.022335","article-title":"Uncertainties of routine HLA B\u22175701 testing in black African HIV cohorts in the UK","volume":"83","author":"Sadiq","year":"2007","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.jaad.2010.01.061_bib73","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","article-title":"Clinical and immunogenetic correlates of abacavir hypersensitivity","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS"},{"issue":"RR-9","key":"10.1016\/j.jaad.2010.01.061_bib74","first-page":"1","article-title":"Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis","volume":"54","author":"Panlilio","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2010.01.061_bib75","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaad.2003.09.033","article-title":"Sweet's syndrome following abacavir therapy","volume":"51","author":"Del Giudice","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib76","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/379667","article-title":"Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus\u2013infected patients","volume":"188","author":"Rousseau","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib77","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.292.2.180","article-title":"Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial","volume":"292","author":"Saag","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2010.01.061_bib78","unstructured":"Mondou E, Quinn JB, Shaw A, Hinkle J, Adda N, Rousseau F. Incidence of skin discoloration across phase III clinical trials of emtricitabine (FTC). Presented at the XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004."},{"key":"10.1016\/j.jaad.2010.01.061_bib79","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1368-5031.2004.00100.x","article-title":"Emtricitabine (FTC) for the treatment of HIV infection","volume":"58","author":"Nelson","year":"2004","journal-title":"Int J Clin Pract"},{"year":"2008","series-title":"Viread [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib80"},{"key":"10.1016\/j.jaad.2010.01.061_bib81","unstructured":"Staszewiski S, Gallant J, Pozniak AL, Sulieman JMAH, De Jesus E, Koenig E, et\u00a0al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. Presented at the XIVth International AIDS Conference, Barcelona, Spain, July 7-12, 2002."},{"key":"10.1016\/j.jaad.2010.01.061_bib82","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/QAD.0b013e32811ebf9e","article-title":"Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases","volume":"21","author":"Lockhart","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib83","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients","volume":"32","author":"Lichtenstein","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.01.061_bib85","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1086\/422141","article-title":"Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy","volume":"39","author":"Duval","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.01.061_bib86","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/00002030-199710001-00008","article-title":"Hypersensitivity reactions during antiretroviral regimens with protease inhibitors","volume":"11","author":"Bonfanti","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1345\/aph.18160","article-title":"Characterization of rash with indinavir in a national patient cohort","volume":"33","author":"Gajewski","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2010.01.061_bib88","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM199908193410818","article-title":"Alopecia associated with indinavir therapy","volume":"341","author":"Bouscarat","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib89","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199806113382417","article-title":"Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir","volume":"338","author":"Bouscarat","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.01.061_bib90","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2165\/00002018-200225140-00002","article-title":"Indinavir-induced retinoid-like effects: incidence, clinical features and management","volume":"25","author":"Garcia-Silva","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2010.01.061_bib91","first-page":"292","article-title":"Cutaneous side effects induced by indinavir","volume":"10","author":"Calista","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib92","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1345\/aph.10386","article-title":"Recurrent ingrown toenails secondary to indinavir\/ritonavir combination therapy","volume":"35","author":"James","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2010.01.061_bib93","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0006-2952(00)00246-X","article-title":"Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir","volume":"59","author":"Lenhard","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaad.2010.01.061_bib94","doi-asserted-by":"crossref","first-page":"F37","DOI":"10.1097\/00002030-199806000-00001","article-title":"Indinavir-associated lipodystrophy","volume":"12","author":"Viraben","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib95","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1 pt 1","key":"10.1016\/j.jaad.2010.01.061_bib96","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0190-9622(00)90021-5","article-title":"Protease inhibitor-associated angiolipomatosis","volume":"42","author":"Dank","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib97","first-page":"296","article-title":"Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection","volume":"10","author":"Cohen","year":"2000","journal-title":"AIDS Read"},{"key":"10.1016\/j.jaad.2010.01.061_bib98","first-page":"91","article-title":"HIV-related drug metabolism and cytochrome P450 enzymes","volume":"12","author":"Andrade","year":"2000","journal-title":"AIDS Clin Care"},{"key":"10.1016\/j.jaad.2010.01.061_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaad.2010.01.061_bib100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","article-title":"Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group","volume":"351","author":"Cameron","year":"1998","journal-title":"Lancet"},{"year":"2008","series-title":"Norvir [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib101"},{"key":"10.1016\/j.jaad.2010.01.061_bib102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00002030-199902040-00009","article-title":"Ritonavir and saquinavir combination therapy for the treatment of HIV infection","volume":"13","author":"Cameron","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib103","first-page":"29","article-title":"Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor","volume":"66","author":"Smith","year":"2000","journal-title":"Cutis"},{"year":"2007","series-title":"Viracept [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib104"},{"key":"10.1016\/j.jaad.2010.01.061_bib105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0091-6749(98)70031-4","article-title":"Nelfinavir-induced urticaria and successful desensitization","volume":"102","author":"Demoly","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2010.01.061_bib106","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00002030-200002180-00024","article-title":"Rash as side-effect of nelfinavir in children","volume":"14","author":"Fortuny","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib107","first-page":"97","article-title":"Maculo-papular rash induced by lopinavir\/ritonavir","volume":"15","author":"Calista","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2010.01.061_bib108","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/QAD.0b013e328010f212","article-title":"Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function","volume":"20","author":"Manfredi","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.01.061_bib109","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/135965350000500306","article-title":"Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team","volume":"5","author":"Goodgame","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jaad.2010.01.061_bib110","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.clinthera.2006.05.011","article-title":"Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir\/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study","volume":"28","author":"Gathe","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2010.01.061_bib111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200401010-00003","article-title":"The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients","volume":"35","author":"Rodriguez-French","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"year":"2008","series-title":"Lexiva [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib112"},{"key":"10.1016\/j.jaad.2010.01.061_bib113","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.01.061_bib114","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/00002030-200312050-00007","article-title":"Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results","volume":"17","author":"Murphy","year":"2003","journal-title":"AIDS"},{"year":"2008","series-title":"Reyataz [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib115"},{"key":"10.1016\/j.jaad.2010.01.061_bib116","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2165\/00003495-200868100-00006","article-title":"Tipranavir: a review of its use in the management of HIV infection","volume":"68","author":"Orman","year":"2008","journal-title":"Drugs"},{"year":"2008","series-title":"Aptivus [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib117"},{"key":"10.1016\/j.jaad.2010.01.061_bib118","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2146\/ajhp060668","article-title":"Darunavir: a second-generation protease inhibitor","volume":"64","author":"Busse","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaad.2010.01.061_bib119","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.01.061_bib120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","article-title":"Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3","volume":"46","author":"Molina","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"year":"2006","series-title":"Prezista [package insert]","key":"10.1016\/j.jaad.2010.01.061_bib121"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210003804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210003804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:17:01Z","timestamp":1759270621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210003804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0190962210003804"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.01.061","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous toxicities of antiretroviral therapy for HIV","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.01.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}